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EDITORIAL
Quality improvement for cancer multidisciplinary teams:
lessons learned from the Anglian Germ Cell Cancer
Collaborative Group
Shamash and colleagues describe how their supra-regional germ cell tumour multidisciplinary team achieved standardisation
of treatment and improved survival. We discuss some of the insights the study provides into prioritising complex patients,
streamlining processes, the use of telemedicine, and the centrality of good data collection to continuous quality improvement.
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MAIN
In the months before the coronavirus disease 2019 (COVID-19)
pandemic, multidisciplinary team (MDT) working in cancer care
was again on the stakeholder’s agenda. Interest had been piqued
with the Gore report,1 which called for a change in the way
MDTs worked to meet the challenges of increasing workload,
while maintaining quality. Since the 1990s, the United Kingdom’s
system of MDT working with networks of MDTs and cancer centres
(and for rare tumours, of supra-network MDTs) has become the
gold standard and a model for other countries.
Shamash and colleagues2 describe the impact of a supra-
network MDT (SMDT) on clinical decision-making and outcomes
for patients with germ-cell tumours in the east of England.
Although all patients with a diagnosis of germ-cell tumour were
discussed at the MDT meeting, patients with favourable features
were discussed briefly, permitting more time for discussion of
complex cases. Patients needing emergency treatment were
discussed with the chair outside the meeting to ensure timely
initial therapy. MDTs across the region met weekly via video
conferencing. Oversight was provided through annual governance
meetings, which included reviews of operational policy and
clinical trials. Importantly, a standardised proforma was developed
and used for submission of patient details to the SMDT, which also
formed the basis of data submitted for their manuscript.2
Between 2007 and 2017, 2892 new cases of germ-cell tumour
were reviewed by the SMDT. Although changes to radiological
and pathological reports and recommendations for patient
management were seldom made (3, 5.4, and 6.4%, respectively),
other benefits of the supra-regional network are apparent.2
Overall survival at lower-volume centres (87.8–93.3%) increased
to that of higher-volume centres (95%). Improvements arose from
standardisation of chemotherapy regimens, increased adoption of
novel regiments, and more equitable access to such treatments.
18-Fluorodeoxyglucose positron emission tomography/computed
tomography was found to be less useful than previously
described. An additional benefit of the SMDT was as a focus to
improve the outcome of smaller centres as an alternative to
further centralisation of services.2
The data presented by Shamash and colleagues2 also gives an
insight into the organisation of a complex but well-functioning
network covering numerous sites and different specialists over a
significant geographical location. This group had put into practice
the suggestions set out in the Gore report1 years ahead of
publication.
Taking each of these individually:
Focussing on complex cases
The greatest benefit of MDT working is seen in complex cases, e.g.
unusual subtype of disease, failure of previous treatment,
significant comorbidities, and social or psychological problems.2
These patients often do not fit guidelines, are not eligible for
clinical trials, and can be challenging to engage in healthcare
services. Shamash et al.2 highlight patients with learning
difficulties or mental health problems and those with late relapses
each present problem that are less commonly addressed and
require tailored individualised treatment plans. These findings are
in line with the recent study on what constitute a complex case for
MDT discussion, mirroring those found to be indicators of
complexity across a range of tumour types.3 Although they
represent a small portion of cases, considerable amount of
additional support is needed before and after diagnosis and
treatment.2
Shamash and colleagues2 set out criteria for cases that may not
need full discussion in the MDT meeting. It may be desirable to go
further and identify cases that are truly ‘complex’ and those that
are ‘simple’. Recently, Soukup and colleagues3 published work on
the development and validation of a tool for stratifying cases by
complexity, which might allow teams to streamline their caseload
in a scientific manner. Further research is needed to assess its
impact on patient care and the efficiency of MDT processes.
The inclusion of information on patients’ comorbidities and
psychological and social factors that may impact care are
persistently, poorly represented in MDT meetings.4 Such informa-
tion, as well as that which focusses on the disease in question, is
necessary for comprehensive clinical management planning.5
These findings support the conclusions by Shamash and
colleagues,2 that patients with complicating features require
holistic discussion in order to develop tailored treatment plans.
Using chair’s action to facilitate urgent treatment
The time between meetings can present a significant period for
patients with rapidly progressing disease waiting for MDT review
and recommendations.2 In such cases, the MDT chair is well
placed to endorse management proposals of clinicians out with
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the MDT meeting in order to avoid delays.2 Such cases should still
be registered with the MDT and could be reviewed post hoc. The
responsiveness of an MDT to clinical or organisational pressures is
an area fertile for improvement.
The use of videoconferencing to improve collaborative decision-
making
Videoconferencing has been controversial in MDT meetings, and
Shamash and colleagues2 discuss some of its advantages and
challenges. Regular SMDT meetings are not feasible without some
form of remote contact.2 Technology failure and differences in
communication styles can present challenges to the quality of
MDT decision-making.6 Perhaps a lasting legacy of COVID-19 will
be the dramatic shift towards telemedicine, replacing many face-
to-face interactions. Interestingly, Shamash and colleagues2 note
the benefits of a yearly meeting at which members of the SMDT
can interact and discuss matters of importance. Many MDTs now
manage to operate remotely via video link. It may be desirable to
supplement this with periodic face-to-face interaction that permit
more nuanced communication regarding performance, opera-
tional policy, challenges, and future directions.
Data collection and audit
The careful, planned collection of clinical and process data was
crucial for assessing complex areas of healthcare, such as care
pathways and organisational changes.2 Recent NHS England and
NHS Improvement report7 has highlighted that data collection
and regular audit must accompany MDT transformation. As
Shamash and colleagues2 showed, the collection and analysis of
such data might provide a resource to benchmark processes and
outcomes, thereby driving standardisation and convergence
towards best practice. Well-designed data collection supports
quality improvement and clinical research, driving the develop-
ment of new and better standards of care. Ultimately, this will
provide high-quality information to patients and their doctors,
enabling shared decision-making of the highest quality.
AUTHOR CONTRIBUTIONS
B.W.L. and T.S. conceived of and drafted the manuscript. J.S.A.G. and N.S. provided
revision of the manuscript.
ADDITIONAL INFORMATION
Ethics approval and consent to participate Ethical approval is not applicable for
this editorial piece.
Data availability Not applicable.
Competing interests B.W.L. and T.S. received funding for training multidisciplinary
teams in assessment and quality improvement methods in the United Kingdom. T.S.
serves as a consultant to F.H.-L.R. Diagnostics providing advisory research services in
relation to innovations for multidisciplinary teams and their meetings. N.S. is the
Director of London Safety & Training Solutions Ltd, which provides patient safety and
quality improvement training and advisory services on a consultancy basis to
hospitals and training programs in the UK and internationally. J.S.A.G. is the Director
of Green Cross Medical Ltd that developed MDT FIT for use by National Health
Service Cancer Teams in the UK. The other authors have no conflicts of interest to
report.
Funding information N.S. is funded by the NIHR via the ‘Applied Research
Collaboration: South London’ at King’s College Hospital NHS Foundation Trust,
London, UK. N.S. is also a member of King’s Improvement Science, which offers co-
funding to the NIHR ARC South London and comprises a specialist team of
improvement scientists and senior researchers based at King’s College London. Its
work is funded by King’s Health Partners (Guy’s and St Thomas’ NHS Foundation
Trust, King’s College Hospital NHS Foundation Trust, King’s College London, and
South London and Maudsley NHS Foundation Trust), Guy’s and St Thomas’ Charity,
and the Maudsley Charity. The funding agreement ensured the authors’ indepen-
dence in designing the study, interpreting the data, writing, and publishing the
report. The views expressed are those of the authors and not necessarily those of the
NHS, NIHR, or the Department of Health and Social Care.
Note This work is published under the standard license to publish agreement. After
12 months the work will become freely available and the license terms will switch to
a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Tayana Soukup 1, Nick Sevdalis1, James S. A. Green1,2 and
Benjamin W. Lamb 3
1Center for Implementation Science, Health Service and Population
Research Department, King’s College London, London, UK; 2Whipps
Cross University Hospital, Barts Health NHS Trust, London, UK and
3Department of Urology, Cambridge University Hospitals NHS
Foundation Trust, Cambridge, UK
Correspondence: Benjamin W. Lamb
(benjamin.lamb@addenbrookes.nhs.uk)
These authors contributed equally: Nick Sevdalis, James S. A. Green
REFERENCES
1. Gore, M. Transforming multidisciplinary team meetings (MDTMs). https://www.
england.nhs.uk/south/wp-content/uploads/sites/6/2018/10/Transforming-MDTM-
Martin-Gore-August-2017.pdf (2017).
2. Shamash, J., Wendy, A., Alifrangis, C., Thomas, B., Wilson, P., Stoneham, S. et al.
The impact of a supranetwork-multidisciplinary team (SMDT) on decision-mak-
ing in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer
Collaborative Group (AGCCCG). https://doi.org/10.1038/s41416-020-01075-1
(2020).
3. Soukup, T., Morbi, A., Lamb, B. W., Gandamihardja, T., Hogben, K., Noyes, K. et al. A
measure of case-complexity for streamlining workflow in cancer multidisciplinary
tumor boards: mixed methods development and early validation of the MeDiC
tool. Cancer Med. 9, 5143–5154 (2020).
4. Lamb, B. W., Brown, K., Nagpal, K., Vincent, C., Green, J. S. A. & Sevdalis, N. Quality of
care management decisions by multidisciplinary cancer teams: a systematic
review. Ann. Surg. Oncol. 18, 2116–2125 (2011).
5. Soukup, T., Lamb, B. W., Sarkar, S., Arora, S., Shah, S., Darzi, A. et al. Predictors of
treatment decision in multidisciplinary oncology meetings: a quantitative obser-
vational study. Ann. Surg. Oncol. 23, 4410–4417 (2016).
6. Soukup, T., Lamb, B. W., Morbi, A., Shah, N. J., Bali, A., Asher, V. et al. A multicentre
cross-sectional observational study of cancer multidisciplinary teams: analysis of
team decision making. Cancer Med. 00, 1–17 (2020).
7. NHS England and NHS Improvement. Streamlining Multi-Disciplinary Team Meet-
ings: Guidance for Cancer Alliances (NHS England and NHS Improvement, London,
2020).
Editorial
314
1
2
3
4
5
6
7
8
9
0
()
;,:
